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Summary 
Professional  antigen-presenting  cells,  such  as  macrophages,  dendritic  cells,  or B  cells,  take  up 
soluble,  exogenous  antigens  (Ags)  and process them through  the  class II pathway,  Several re- 
ports have shown that phagocytic macrophages also process particulate  or soluble forms of ex- 
ogenous Ag via the class I pathway. By contrast, B  cells normally do not process soluble, exog- 
enous Ag by way of the class I pathway unless Ags are directly introduced  into the cytoplasm. 
Here we report that B  cells present exogenous Ag via the class  I pathway when Ags are taken 
up by receptor-mediated  endocytosis.  Thus,  specialized methods of Ag uptake such as phago- 
cytosis or receptor-mediated  endocytosis deliver exogenous Ag into the class I pathway of Ag 
processing and presentation. 
E 
xogenous  Ags  are  taken  up  nonspecifically  by  fluid- 
phase  pinocytosis  or  endocytosis,  processed,  and  pre- 
sented  via class  II pathway  by professional  APCs,  such  as 
macrophages, dendritic  cells, or B  cells. Exogenous Ags do 
not enter the class I pathway of most cells (1-3).  However, 
a small population  of phagocytic  macrophages  can process 
such Ags via the class I pathway when stimulated with high 
concentrations  (4,  5)  or  particulate  forms  (6-8)  of Ag.  B 
cells normally do  not appear to process soluble  (4)  or par- 
ticulate forms (9) of exogenous Ags via the class I pathway. 
The Ag-specific Ig receptors may have an important role 
not only in the activation of B  cells but also in the efficient 
presentation  of exogenous  Ags  to  T  cells.  For  example, 
hapten-specific B  cells present hapten-carrier conjugates to 
cartier-specific  CD4 +  T  cells  much  more  efficiently  than 
unmodified protein Ags (10). 
The  possibility  that  lg receptors  might  facilitate  uptake 
and processing of exogenous Ags via the class I pathway has 
not been thoroughly investigated.  However, Yefenof et al. 
reported  that  CD8 §  T  cells  from  LNs  of KLH-primed 
mice  lysed  hapten-specific  virgin  B  cells  after  incubation 
with  hapten-KLH  (11).  More  recently,  we  found  that 
adoptive  transfer  of CD8 +  CTLs  suppressed  humoral  re- 
sponses in recipient mice (12).  These observations raise the 
possibility that B  cells might process exogenous Ag via the 
class  I  pathway  if Ags  are  taken  up  by receptor-mediated 
endocytosis. The current studies explored this possibility by 
using  a  hapten-carrier  system to  study  Ag processing  and 
presentation by B  cells. 
Materials and Methods 
Antigens and Reagents.  Chicken egg OVA, TNP, chloroquine, 
brefeldin A, and phenazine methosulfate (PMS)  were purchased 
from Sigma Chemical Co. (St. Louis, MO). Crystallized beef in- 
sulin was purchased from Lilly Research Labs (Indianapolis, IN). 
TNP was conjugated to OVA or insulin  as described (13). Tetra- 
zolium salt XTT was obtained from Diagnostics Chemicals Ltd. 
(Oxford,  CT).  N-acetyl-L-leucinyl-L-leucinal-L-norleucinal  (LLnL) 
and N-acetyl-L-leucinyl-L-leucunyl-methional (LLM)  were pro- 
vided by Dr. K.L. Rock (Harvard University, Boston, MA). 
Antibodies.  Culture  supernatants  from  B  cell  hybridomas 
were used as sources of mAb. Anti-SP6 is a mAb specific for the 
idiotype of IgMTN  v (provided by Dr. N. Hozumi, University of 
Toronto,  Toronto,  Ontaro,  Canada).  MK-D6  (anti-I-A  d)  was 
obtained  from  the  American  Type Culture  Collection  (R.ock- 
ville,  MD).  DO4  (anti-KdDd),  25-%35  (anti-I-Ab), and  270-JS 
(anti-K  b) were provided by Dr. V. Hauptfeld (St. Louis Univer- 
sity, St. Louis, MO). 
Cells and Cell Cultures.  A  HAT-sensitive variant of M12.4.1 
(H-2a), a B  cell  lymphoma producing surface  IgG of unknown 
specificity (14), was provided by Dr. R. Asofsky (National Insti- 
tutes of Health, Bethesda, MD). F8.11  is a B cell hybridoma pro- 
duced by fusion of M12.4.1  and spleen ceils from C57BL/6 (H-2  b) 
mice (15).  SP6/HL is a B  cell hybridoma provided by Dr.  Ho- 
zumi. It secretes IgM, K specific  for TNP, and it reacts  with the 
anti-SP6  mAb  directed  toward  idiowpic  determinants  (16). 
E.G7-OVA  (provided by Dr.  M.J.  Bevan, University of Wash- 
ington, Seattle,  WA) was produced by transfection of EL4 (H-2  b) 
with the OVA cDNA gene (17). EL4-INS was produced in our 
laboratory by transfecting EL4 with the genomic human insulin 
gene (18). Two T cell hybridomas, 4B10 (CD8 +, specific for K  b- 
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OVA26s_280) (15), were used as reporter systems for the class I and 
class  II  presentation of OVA,  respectively.  An insulin-specific, 
CD8 +, MHC class I-restricted CTL line was generated by prim- 
ing C57BL/6 mice with beef insulin  in CFA and stimulating  with 
EL4-INS as we described previously (18). All cells were cultured 
in RPMI 1640 containing 10% FCS,  1 mM t-glutamine, 1 mM 
Na-pyruvate, 50 txM 2-ME at 37~  in 6% CO_, in air. 
Vector and Gene Transfer.  F8.11  cells  were  transfected  with 
pR-HLTN ~ vector containing  the structural genes for the Ix and K 
chains  of TNP-specific IgM from SP6/HL and the  neomycin- 
resistance  gene  (19). G418-resistant transfectants,  designated  as 
FS. 11HL, were selected and cloned by limiting dilution. 
Measurement of Abs.  Secretion ofTNP-specific Ab by various 
cell lines was  tested  by ELISA.  In brief,  microtiter plates were 
coated  with  OVA or TNP-OVA and then blocked with  PBS 
plus 1% BSA. Serially diluted supernatants  were added and incu- 
bated  at  37~  for  t  h.  Alkaline phosphatase-conjugated goat 
anti-mouse IgM was then added  and incubated at 37~  for  1 h. 
Finally, p-nitrophenyl phosphate  substrate was added, and colori- 
metric reaction was read as absorbance  at 405 nm using an auto- 
matic microplate reader (Molecular Devices,  Menlo Park, CA). 
Ag Presentation Assay.  In most experiments,  IL-2 production 
by T cell hybridomas was used as a measure of Ag-induced acti- 
vation. T  cells were  cocultured with irradiated  (10,000  rads) B 
cell hybridomas in 96-well plates with or without Ag.  In some 
cases, B cell hybridomas were pretreated  with mAbs or inhibitors 
before  incubation with Ag and T  cells. Supernatants  were har- 
vested after a 24-h incubation at 37~  and IL-2 production was 
tested with HT-2 cells (20) by using XTT plus PMS (21). Absor- 
bance was read at 450 nm, and data were averages of triplicates --_ 
SD. Representative experiments that have been repeated  at least 
three times are shown. 
Cytotoxicity Assay.  Cytotoxicity assays were performed with 
S*Cr-labeled  B  cell  hybridomas  as  targets  and  insulin-specific 
CTLs as effectors (18). Labeled target cells were plated in 96-well 
round-bottomed plates at  104 cells per well and incubated with 
various  concentrations of Ag at 37~  for  1 h.  CTLs were then 
added to the plates at an E/T ratio  of ~%. After a 4-h incubation 
at 37~  supernatants  were harvested,  and radioactivity  was de- 
tected in a gamma counter (Wallac, Turku, Finland). The per- 
centage specific lysis equals 100 X ([release by CTLs -  spontane- 
ous  releasel/[maximal release  -  spontaneous release]). Maximal 
release was detemfined by addition of 1% Triton X-100. Sponta- 
neous release in the absence of CTLs was <15% of maximal re- 
lease. Representative experiments that have been repeated  at least 
three  times are shown. 
Results and Discussion 
Characterization of B Cells Expressing Anti: TNP mIg Recep- 
tors.  B  cells,  like  most  other  somatic  cells,  do  not  effi- 
ciently take up and process soluble, exogenous Ag into the 
class I pathway (1).  The purpose of these studies was to de- 
termine definitively whether B  cells can take up and pro- 
cess  exogenous Ag via the  class  I pathway if Ag uptake is 
facilitated by receptor-mediated endocytosis. For this pur- 
pose, we wanted to use a B cell line that expresses high lev- 
els  of  membrane  lg  (mlg)  of  a  known  specificity.  We 
thought  it  was  also  important that  the  mlg-expressing B 
cells should not secrete significant amounts of Ab, because 
formation of Ag-Ab complexes would introduce ambigu- 
ities into the  interpretation of these  experiments. For ex- 
ample, such complexes might decrease the amount of avail- 
able Ag or alternatively increase the amount of Ag taken up 
ifB cells expressed FcP,.  Therefore, we  chose M12.4.l  B 
cell lymphoma for  the  starting cells.  This tumor arose  in 
BALB/c mice and expresses both MHC  class I and MHC 
class II Ag (14).  In addition, M12.4.1 expresses mlgG of an 
unknown specificity (J.A.  Kapp, unpublished observations) 
but does  not secrete  Ig  (14).  A  HAT-sensitive variant of 
M12.4.1  was fused with SCs from C57BL/6 mice injected 
with LPS. This fusion gave rise to a hybridoma (F8.11) that 
expresses MHC class l and class II Ag from both H-2  b and 
H-2  d haplotypes (15). 
F8.11  was  subsequently transfected  by  electroporation 
with  a  plasmid  (plk-HLTNP)  containing the  rearranged  Ix 
and K genes cloned from genomic DNA of SP6/HL  (19). 
Hozumi and colleagues have previously shown that trans- 
fection orB cell hybridomas with this plasmid yielded cells 
that secreted TNP-specific IgM (16). By contrast, transfec- 
tion  of A20-2J,  a  B  lymphoma line,  with  this  construct 
produced cells  expressing TNP-specific mlgM (19).  Thus, 
these  results illustrate that  the  phenotype of the  recipient 
cell dictates differential mRNA  processing of the  I  x  chain 
(22,  23).  Neomycin-resistant transfectants were  identified 
by rosette  formation with  TNP-conjugated sheep  RBCs 
and binding of fluoresceinated anti-SP6, an idiotype-spe- 
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Figure 1.  Production ofs][glVITN  I, by SP6/HL but not F8.11HL. Super- 
natants from SP6/HL (O), F8.11 (+), or F8.l 1HL (<)) were serially di- 
luted and tested for Abs against  TNP-OVA (A) or OVA (/3) by ELISA. 
Normal mouse lgM (O) and serum from mice primed with OVA in CFA 
(0) were used at a starting  dilution of ~.. Bound Ab was detected by al- 
kaline phosphatase-conjugated  goat anti-mouse IgM and p-nitrophenyl 
phosphate substrate. Absorbance  was read at 405 ran. 
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Figure 2.  Ag presentation by B cells. In microtiter plates, 5 X 10  ~ of 
4B10 (A and C) or 2D5  (B and D) were incubated with 10  s irradiated 
(10,000 fads) FS.11HL (A and 13) or F8.11 (C and D) cells in the presence 
of  serially  diluted TNP-OVA (O) or native OVA (O). Irradiated EL4 ([3) 
and E.G7-OVA (~), added at 5 X 104/well to T cell hybridomas with- 
out exogenous Ag, were used as negative and positive controls for class 
I-restricted  responses and as negative controls for class /I-restricted  re- 
sponses. After a 24-h incubation at 37~  supernatants  were tested for IL-2 
production by using HT-2 cells in a colorimetric assay. Absorbance was 
read at 450 nm. The results shown are averages of triplicates +  SD. 
cific Ab (not shown).  The transfectant (F8.11HL) that was 
selected  for  cell  surface  expression  of anti-TNP  Ig  was 
tested  for  secretion  of  IgMTNp  (slg).  Supernatants  were 
tested  for  TNP-specific Abs by ELISA.  SP6/HL  secreted 
anti-TNP Abs, whereas neither F8.11  nor F8.11HL did so 
(Fig.  1),  indicating that  F8.11HL  cells produce  mlgMTNP 
but not slgMTNP. Thus, F8.11HL could be used to provide 
APCs  without  concern  that  secreted  Ab  might  interfere 
with the interpretation of the results. 
B  Cells Expressing mlg Receptors Process Exogenous Ag via 
The Class I Pathway.  The ability ofmlg-bearing B  cells to 
present exogenous Ag via the class I pathway was first tested 
by  using  the  OVA257_264-specific,  CD8 +,  Kb-restricted 
T-cell hybridoma 4B10.  Stimulation of4B10  by F8.11HL 
was dose dependent when incubated with TNP-OVA  but 
not native OVA  (Fig. 2  A), whereas B  cells lacking mlg- 
MTNP receptors (F8.11) did not stimulate 4B10 with either 
OVA  or  TNP-OVA  (Fig.  2  C).  These  data  suggest  that 
uptake  of TNP-OVA  into the  class I  pathway was medi- 
ated by mlgMTN P receptors. For comparison, the ability of 
F8.11 and F8.11HL to process Ag via the class II pathway was 
tested with the OVA26s_280-specific, CD4 +,  [-AU-restricted 
T-cell hybridoma 2D5. As expected, both F8.1 1HL (Fig. 2 
B) and F8.1 1 (Fig. 2 D) presented TNP-OVA  and OVA to 
2D5. As shown by others (10,  19, 24), B  cells bearing hap- 
ten-specific receptors presented haptenated Ag to CD4 + T 
cells much more efficiently than unmodified Ag (Fig. 2  B). 
B  cells  lacking  mlgMxN~  receptors  presented  haptenated 
and  unmodified  OVA  to  2D5  equally well (Fig.  2  D).  It 
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Figure 3.  Class I presentation of insulin by B cells. In microtiter plates, 
104 per well of S~Cr-labeled  F8.11HL (A) or F8.11 (B) targets were first 
incubated with serially titrated TNP-insulin (0) or native insulin (￿9  at 
37~  for 1 h. Insulin-specific, CD8 + CTLs were then added at an E/T 
ratio of 10/1. SlCr-labeled EL4--INS (') and EL4 (V1) targets, added at 
104 per well to insulin CTLs without exogenous Ag, were used as posi- 
tive and  negative controls for  class I-restricted  responses. The  results 
shown are the % specific  lysis  representing averages of triplicates •  SD. 
should  be  noted  that  presentation  of  TNP-OVA  by 
F8.11HL to CD4 + T  cells (2D5) was --,100-fold more effi- 
cient than presentation to CD8 + T  cells (4B10). 
We wanted to determine whether presentation of exog- 
enous  Ag via the class I  pathway by mlgMTNp-beailng B 
cells was unique for OVA or generalizable. Thus, these ex- 
periments were repeated with an insulin-specific CTL line 
(18).  As  shown  in  Fig.  3  A,  F8.11HL  cells pulsed  with 
TNP-insulin,  but  not  unmodified insulin,  were  killed by 
the  CD8 +  CTL.  F8.11HL  cells pulsed  with  TNP-OVA 
were not killed by the insulin-specific CTLs  (not shown). 
By contrast, F8.11  cells pulsed with either TNP-insulin or 
insulin were not killed by these CTLs (Fig. 3 B). These re- 
sults demonstrate that processing via the class I  pathway is 
not unique to OVA. Moreover, these data show that pro- 
cessing via the class I pathway renders B  cells susceptible to 
lysis by CTLs. 
Inhibition of Class I or Class II Presentation of Exogenous Ag 
by B Cells.  To  verify  that  mlgMTNP  receptors  were  re- 
sponsible for class I  presentation of TNP-OVA,  F8.11HL 
cells were pretreated with anti-Id mAb. Anti-SP6 inhibited 
presentation of TNP-OVA  to both  CD8 +  (Fig. 4  A)  and 
CD4 § T  cells (Fig. 4  B). As expected, anti-SP6 did not in- 
hibit presentation  of native OVA  to  CD4 +  T  cells, since 
uptake is by endocytosis and not facilitated by mlg recep- 
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Figure 4.  Inhibition  of Ag presentation by B cells. In microtiter plates, 
105 irradiated (10,000 rads) F8.11HL cells per well were either untreated 
or pretreated with the following: (A and B) anti-SP6 or (C and/7)) anti- 
MHC Ab at 4~  for 1 h, or (E and F) inhibitors (1 btg/ml brefeldin A, 
12.5 }xM chloroquine, 12.5 IxM LLM or 12.5 }xM LLnL) at 37~  for 1 h. 
Ag and 5 ￿  10  "4 T cells per well were then added. On the basis of the ti- 
tration curves in Fig. 2, TNP-OVA and OVA were used at 2I)0 IXg/ml 
for class l presentation (A, C, and E). TNP-OVA and OVA were used at 
20 Ixg/ml and 200 btg/nfl for class II presentation (B, D, and F), respec- 
tively. After a 24-h incubation at 37~  supernatants were tested for IL-2 
production, and the results are shown as the averages of triplicates + SD. 
tors  (Fig.  4  B).  The  role  of mlgMrN  e  receptors  was  also 
verified by the  observation that TNP  conjugated to other 
proteins, such as BSA, competitively inhibited presentation 
of TNP-OVA  to  both  CD4 §  and  CD8 §  T  cells  (not 
shown).  Abs specific for MHC  class  I  or II Ags were also 
used  to  determine  whether  stimulation  of  CD4 +  and 
CD8 +  T  cells  by  B  cells  represented  classically  defined 
complexes  of MHC  and  peptides.  Presentation  of TNP- 
OVA to  CD8 §  T  cells  was  inhibited  by anti-K  b Abs but 
not by Ab specific for KaD  d or class  II Ag, both of which 
are also expressed by F8.11ILL (Fig. 4  C). However, stimu- 
lation of CD4 + T  cells was inhibited by anti-I-A  b Ab but 
not by Abs specific for I-A  a or class I Ag (Fig. 4 D). These 
results  verify that  receptor-mediated  endocytosis results  in 
processing of OVA peptides  that are complexed with both 
MHC class I and MHC class II molecules. 
Several inhibitors were used to determine  whether pre- 
sentation  of TNP-OVA  followed  the  classically  defined 
pathway for class I or class II processing. The class I inhibi- 
tor brefeldin A  (25) blocked presentation of TNP-OVA by 
F8.11HL to CD8 + 4B10 (Fig. 4 E) but not to CD4 + 2D5 
(Fig. 4  F). By contrast, weak bases such as chloroquine in- 
hibited  presentation  of TNP-OVA  by  F8.11HL  to  2D5 
(Fig. 4 F) but not to 4B10 (Fig. 4 E). Recently, Rock et al. 
showed that class  I processing of electroporated OVA was 
inhibited  by peptide  aldehyde  LLnL but  not  by  LLM,  a 
closely related analogue  (26). Although both aldehydes are 
reported  to  inhibit  lysosomal proteases,  several  lysosomal 
inhibitors  failed to inhibit  the  class  I  pathway  (26).  Thus, 
these authors concluded that proteasomal processing gener- 
ates the peptides presented by MHC  class I molecules. Our 
data show that class I processing of TNP-OVA  taken up by 
receptor-mediated  endocytosis  was  similarly  inhibited  by 
LLnL but not by LLM (Fig. 4 E), whereas class II process- 
ing of TNP-OVA  was inhibited  by both LLnL and LLM 
(Fig.  4  F).  The  latter  observation  is  not  surprising,  given 
that both aldehydes are potent inhibitors of lysosomal pro- 
cessing (26). Neither LLnL nor LLM inhibited presentation 
ofOVA257_264 or OVA26s_281/peptides to CD8 + or CD4 + T 
cells,  respectively. Thus, these inhibitors are not nonspecif- 
ically toxic (not shown). 
The present study suggests that exogenous Ags taken up 
by ligand-mediated  endocytosis of mlg receptors are shut- 
tled from the endosomal compartment into the cytosol for 
class  I  processing.  Barnaba  et  al.  reported  that  hepatitis  B 
envelope (Hbenv)-specific B  cells  presented exogenous Ag 
to  Hbenv-specific  MHC-restricted  CD8 +  T  cells  (27). 
However, normal B  cells  also presented Hbenv, unlike our 
findings for OVA. These investigators have shown that the 
transferrin  receptor  (TfR)  is  required  for  the  uptake  and 
processing of Hbenv into  the  class  I  and  class  II pathways 
by activated human T  cells  (28). Moreover, uptake via the 
TfR  requires  binding  of Hbenv  to  transferrin  (29).  This 
pathway  of peptide  binding by transferrin  and  subsequent 
uptake  by TfR  is  probably  unique  for  Hbenv  and  not  a 
common  route  for  uptake  of exogenous  Ag  by  APCs. 
Nevertheless,  these  data  and  our studies  provide  evidence 
that  uptake  of exogenous  Ag  by  receptor-mediated  en- 
docytosis supplies peptides to the class I and class II process- 
ing pathways. 
By contrast to transferrin-mediated  uptake,  B  cells lack- 
ing  mlgMTN P  receptors  did  not  present  TNP-OVA  to 
CD8 + T  ceils,  nor did B  cells  expressing mlgMTNp recep- 
tors present unmodified OVA to CD8 + T  ceils.  Similar re- 
suits  were  obtained  with  insulin-specific  CTLs,  demon- 
strating that this form of presentation is not limited to OVA 
or CD8 +, MHC class I-restricted T  ceils specific for OVA. 
Thus, Ags that have no known mechanisms for gaining ac- 
cess to the cytosol can be processed via the class I pathway 
ifAgs are taken up by receptor-mediated endocytosis. How 
and where  the Ags traverse  from the  endosomal compart- 
ment into the  cytosol is unknown, but processing is inde- 
pendent of acidification; otherwise, chloroquine would have 
inhibited  class  I  presentation.  This  mode  of presentation 
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the cytosol within macrophages, as demonstrated by other 
investigators (7, 9). 
The  physiological consequences  of class I  processing of 
exogenous Ag by specific B  cells remain to be determined. 
Many investigators have reported that CD8 +  T  cells, acti- 
vated by exogenous Ags, specifically suppress humoral re- 
sponses  and  cell-mediated immune  responses.  This  phe- 
nomenon  has  been  puzzling,  in  part,  because  exogenous 
Ags were not thought to be processed via the class I path- 
way.  However,  macrophages  are  now  known  to  process 
exogenous Ag via the class I pathway and Ag bound to in- 
ert beads (6)  or emulsified in CFA (12)  prime MHC  class 
I-restricted  CD8 +  CTLs.  Moreover,  CD8 +  CTLs  have 
been  shown  to  inhibit  responses  to  exogenous  Ag  by 
CD4 + T  cells in vitro (30)  and Ab responses in vivo (12). 
Inhibition  is  likely  caused  by  lysis  of APCs.  Taken  to- 
gether,  our  data demonstrate  that  Ag-specific B  cells also 
can serve as targets for regulation by CD8 § T  cells. 
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